These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32430632)

  • 1. Synthesis, in vitro and in vivo evaluation of
    Narayanaswami V; Tong J; Fiorino F; Severino B; Sparaco R; Magli E; Giordano F; Bloomfield PM; Prabhakaran J; Mann JJ; Vasdev N; Dahl K; Kumar JSD
    EJNMMI Radiopharm Chem; 2020 May; 5(1):13. PubMed ID: 32430632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging.
    Lemoine L; Becker G; Vacher B; Billard T; Lancelot S; Newman-Tancredi A; Zimmer L
    J Nucl Med; 2012 Jun; 53(6):969-76. PubMed ID: 22577236
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Vidal B; Fieux S; Colom M; Billard T; Bouillot C; Barret O; Constantinescu C; Tamagnan G; Newman-Tancredi A; Zimmer L
    Brain Struct Funct; 2018 Jul; 223(6):2973-2988. PubMed ID: 29730825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (11)C-CUMI-101, a PET radioligand, behaves as a serotonin 1A receptor antagonist and also binds to α(1) adrenoceptors in brain.
    Shrestha SS; Liow JS; Lu S; Jenko K; Gladding RL; Svenningsson P; Morse CL; Zoghbi SS; Pike VW; Innis RB
    J Nucl Med; 2014 Jan; 55(1):141-6. PubMed ID: 24385311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and initial evaluation of [11C](R)-RWAY in monkey-a new, simply labeled antagonist radioligand for imaging brain 5-HT1A receptors with PET.
    McCarron JA; Zoghbi SS; Shetty HU; Vermeulen ES; Wikström HV; Ichise M; Yasuno F; Halldin C; Innis RB; Pike VW
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1670-82. PubMed ID: 17579853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human evaluation of 18F-mefway, a PET radioligand specific to serotonin-1A receptors.
    Hillmer AT; Wooten DW; Bajwa AK; Higgins AT; Lao PJ; Betthauser TJ; Barnhart TE; Rowley HA; Stone CK; Johnson SC; Mukherjee J; Christian BT
    J Nucl Med; 2014 Dec; 55(12):1973-9. PubMed ID: 25453045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 4 radiolabeled antagonists for serotonin 5-HT(7) receptor neuroimaging: toward the first PET radiotracer.
    Lemoine L; Andries J; Le Bars D; Billard T; Zimmer L
    J Nucl Med; 2011 Nov; 52(11):1811-8. PubMed ID: 21990574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: a new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines.
    Perrone R; Berardi F; Colabufo NA; Leopoldo M; Lacivita E; Tortorella V; Leonardi A; Poggesi E; Testa R
    J Med Chem; 2001 Dec; 44(25):4431-42. PubMed ID: 11728188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo.
    Pike VW; Halldin C; McCarron JA; Lundkvist C; Hirani E; Olsson H; Hume SP; Karlsson P; Osman S; Swahn CG; Hall H; Wikström H; Mensonidas M; Poole KG; Farde L
    Eur J Nucl Med; 1998 Apr; 25(4):338-46. PubMed ID: 9553162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Preclinical Evaluation of [
    Dahl K; Johnström P; Forsberg-Morén A; Gustafsson B; Miranda-Azpiazu P; Khani Y; Halldin C; Farde L; Elmore CS; Schou M
    ACS Chem Neurosci; 2022 Jul; 13(14):2078-2083. PubMed ID: 35802379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivatives of WAY 100635 as potential imaging agents for 5-HT1A receptors: syntheses, radiosyntheses, and in vitro and in vivo evaluation.
    Wilson AA; Inaba T; Fischer N; Dixon LM; Nobrega J; DaSilva JN; Houle S
    Nucl Med Biol; 1998 Nov; 25(8):769-76. PubMed ID: 9863565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals.
    Vidal B; Sebti J; Verdurand M; Fieux S; Billard T; Streichenberger N; Troakes C; Newman-Tancredi A; Zimmer L
    Neuropharmacology; 2016 Oct; 109():88-95. PubMed ID: 27183968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
    López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
    J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosynthesis and in vivo evaluation of novel radioligands for PET imaging of cerebral 5-HT7 receptors.
    Hansen HD; Herth MM; Ettrup A; Andersen VL; Lehel S; Dyssegaard A; Kristensen JL; Knudsen GM
    J Nucl Med; 2014 Apr; 55(4):640-6. PubMed ID: 24566002
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.